Cargando…

Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma

BACKGROUND: Bone marrow infiltration of lymphoma cells is a candidate risk factor for infusion-related reactions (IRRs) in patients with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). However, despite with the lack of sufficient data, the effect of bone marrow infiltration of B-NHL cells on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohata, Shinya, Takenaka, Kei, Sugiyama, Daisuke, Sugimoto, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856829/ https://www.ncbi.nlm.nih.gov/pubmed/35189630 http://dx.doi.org/10.1155/2022/3688727

Ejemplares similares

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Assessment of bone marrow infiltration in B-cell non-Hodgkin's lymphoma (NHL).
por: Dorey, E. L., et al.
Publicado: (1989)

Correlation of Patterns of Bone Marrow Infiltration and Biochemical factors in Non-Hodgkin Lymphoma
por: Mazher, Naghmana, et al.
Publicado: (2017)

Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
por: Gilaberte Reyzabal, Sergio, et al.
Publicado: (2022)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
por: Abuelgasim, Khadega A., et al.
Publicado: (2021)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
por: Fozza, Claudio, et al.
Publicado: (2011)

Bone marrow infiltration of lymphoma
por: Kim, Ki Hwan, et al.
Publicado: (2010)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

Transformation of Acute Myeloid Leukemia with Deletion of Chromosome 7q and Additional Abnormalities in Chromosome 8 in a Patient with Essential Thrombocythemia
por: Shimizu, Ayaka, et al.
Publicado: (2021)

How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas
por: Mohammed, Raihan, et al.
Publicado: (2019)

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2013)

Immunocompetent Patient With Primary Bone Marrow Hodgkin Lymphoma
por: Dhaliwal, Armaan, et al.
Publicado: (2022)

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness
por: Badin, Firas, et al.
Publicado: (2010)

Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
por: Wei, Kai-Che, et al.
Publicado: (2018)

Lymphoid Infiltrates in B Cell Non Hodgkin’s Lymphoma: Comparing Nuclear Characteristics between Lymph Node and Bone Marrow; and Evaluating Diagnostic Features of Bone Marrow Infiltrates in Paraffin Embedded Tissues
por: Deverell, Mark H., et al.
Publicado: (1997)

Pituitary infiltration by non-Hodgkin's lymphoma: a case report
por: Tamer, Gonca, et al.
Publicado: (2009)

Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma
por: Hančić, Suzana, et al.
Publicado: (2022)

Concomitant occurrence of genetically distinct Hodgkin lymphoma and primary mediastinal lymphoma
por: Dubois, Sydney, et al.
Publicado: (2021)

Primary non-Hodgkin’s Lymphoma of the Bladder with Bone Marrow Involvement
por: Oh, Kil Chan, et al.
Publicado: (2003)

Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
por: Takeyasu, Yuki, et al.
Publicado: (2017)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Disseminated Intravascular Coagulation-like Reaction after Rituximab Infusion in a Patient with Nephrotic Syndrome
por: Nishiwaki, Hiroki, et al.
Publicado: (2019)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

SEVERE ADENOVIRUS PNEUMONIA IN RITUXIMAB INFUSIONS
por: BJORK, SARAH, et al.
Publicado: (2021)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?
por: Park, Sang-Gon
Publicado: (2019)

Radiotherapy for Non-Hodgkin’s lymphoma with cardiac infiltration: A case report
por: Wang, Weifeng, et al.
Publicado: (2023)

Reed-Sternberg and Hodgkin cells in bone marrow aspirate from a classical Hodgkin lymphoma patient
por: Oliveira, Leonardo Rodrigues, et al.
Publicado: (2022)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_gh39l8imqveve80a4cel9dtv4l